AMENDMENT NO. 1 TO PRE-FUNDED WARRANTPre-Funded Warrant Amendment • May 15th, 2024 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO PRE-FUNDED WARRANT (this “Amendment”) is effective as of April 26, 2023 by and between NLS PHARMACEUTICS LTD., a corporation incorporated under the laws of Switzerland (the “Company”) and the holders of certain Pre-Funded Warrants (as herein defined) as set forth on Appendix A annexed hereto (the “Holder”). Each of the Company and the Holder shall be referred to collectively as the “Parties” and individually as a “Party.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 15th, 2024 • NLS Pharmaceutics Ltd. • Pharmaceutical preparations • New Jersey
This Exclusive License Agreement (the “Definitive Agreement”) is made effective as of March 19, 2024 (the “Effective Date”) by and between Aexon Labs Inc. a Delaware corporation (“Licensor” or “Aexon Labs”), with its principal place of business at 16192 Coastal Hwy, Lewes 19958, DE USA and NLS Pharmaceutics Ltd., a company organized under the laws of Switzerland (“Licensee” or “NLS Pharmaceutics”), with its principal place of business at The Circle 6 I P.O Box, 8058 Zurich Airport Switzerland. Licensee and Licensor are sometimes referred to in this Agreement individually as a “Party” and together as the “Parties.
